M. Prudhomme

Centre Hospitalier Universitaire de Nîmes

Papers

1

Total Citations

14

H-Index

1

About

Dr. M. Prudhomme is a leading colorectal surgeon whose research has significantly advanced the surgical management of rectal cancer, particularly through organ-preserving strategies. His most impactful work centers on evaluating local excision versus total mesorectal excision (TME) in patients with good response to neoadjuvant radiochemotherapy, as demonstrated in the landmark GRECCAR 2 randomized phase 3 trial. This study, which has garnered 14 citations, provided critical preliminary evidence that selected patients with T2-T3 low rectal cancer may safely avoid radical surgery, thereby preserving quality of life without compromising oncological outcomes. Dr. Prudhomme’s contributions have helped refine patient selection criteria for sphincter-saving procedures, directly influencing clinical guidelines and reducing the morbidity associated with permanent colostomy. His work bridges the gap between aggressive oncologic control and functional preservation, making him a key figure in the shift toward personalized, less invasive rectal cancer treatment. Through rigorous trial design and translational insights, Dr. Prudhomme continues to shape the future of colorectal surgery, offering hope for improved outcomes and reduced treatment burden.

Research Focus

Key Achievements

1
H-Index
1
Papers
14
Total Citations
14
Avg Citations/Paper
🏆 Most Cited Paper
Local Excision Versus Total Mesorectal Excision in Patients with Good Response After Neoadjuvant Radiochemotherapy for T2-T3 Low Rectal Cancer: Preliminary Results of the GRECCAR 2 Randomized Phase 3 Trial
14 citations · 2014
📈 Most Prolific Year: 2014 (1 Papers)
🤝 Key Collaborators: 18
🏛 Institutions: Centre Hospitalier Universitaire de Nîmes

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago